<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Insilico Medicine Cayman Topco — News on 6ix</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco</link>
<description>Latest news and press releases for Insilico Medicine Cayman Topco on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 06 Mar 2026 01:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/insilico-medicine-cayman-topco" rel="self" type="application/rss+xml" />
<item>
<title>Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-and-taigen-achieve-milestone-in-collaboration-out-licensed-ckd-anemia-candidate-ism4808-completes-first-human-enrollment-and-dosing-in-phase-i-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-and-taigen-achieve-milestone-in-collaboration-out-licensed-ckd-anemia-candidate-ism4808-completes-first-human-enrollment-and-dosing-in-phase-i-clinical-trial</guid>
<pubDate>Fri, 06 Mar 2026 01:00:00 GMT</pubDate>
<description>Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previously out-licensed to TaiGen Biotechnology (TaiGen*-KY, 4157), has achieved its first milestone. Recently, TaiGen has successfully completed the enrollment and dosing of the first subject in the Phase I clinical trial.</description>
</item>
<item>
<title>AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/ai-powered-randd-acceleration-insilico-medicine-and-cms-announce-multiple-collaborations-in-central-nervous-system-and-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/ai-powered-randd-acceleration-insilico-medicine-and-cms-announce-multiple-collaborations-in-central-nervous-system-and-autoimmune-diseases</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.</description>
</item>
<item>
<title>Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-appoints-halle-zhang-phd-med-as-vice-president-clinical-development-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-appoints-halle-zhang-phd-med-as-vice-president-clinical-development-oncology</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company's Cambridge, Massachusetts office.</description>
</item>
<item>
<title>Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-nominates-ism5059-the-peripheral-restricted-nlrp3-inhibitor-as-preclinical-candidate-for-the-treatment-of-multiple-inflammatory-and-metabolism-indications</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-nominates-ism5059-the-peripheral-restricted-nlrp3-inhibitor-as-preclinical-candidate-for-the-treatment-of-multiple-inflammatory-and-metabolism-indications</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>The NOD-like receptor protein 3 (NLRP3) inflammasome is a validated target for anti-inflammatory drug development. Upon activation by internal and external stimuli, NLRP3 mediates the release of proinflammatory cytokines IL-1β and IL-18, thereby driving a form of inflammatory cell death called pyroptosis. NLRP3 plays an important role in a variety of inflammatory diseases, including metabolic and cardiovascular disorders. Currently, there is a significant unmet clinical need in the treatment of</description>
</item>
<item>
<title>Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-receives-usd-5million-milestone-payment-from-menarini-group-following-first-in-human-fih-achievement-for-men2501</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-receives-usd-5million-milestone-payment-from-menarini-group-following-first-in-human-fih-achievement-for-men2501</guid>
<pubDate>Tue, 03 Feb 2026 14:00:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico"), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group ("Menarini") as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with po</description>
</item>
<item>
<title>Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-and-qilu-pharmaceutical-reach-near-dollar120-million-drug-development-collaboration-to-accelerate-novel-cardiometabolic-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-and-qilu-pharmaceutical-reach-near-dollar120-million-drug-development-collaboration-to-accelerate-novel-cardiometabolic-therapies</guid>
<pubDate>Tue, 27 Jan 2026 14:00:00 GMT</pubDate>
<description>Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.</description>
</item>
<item>
<title>Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-receives-ind-approval-133000218</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-receives-ind-approval-133000218</guid>
<pubDate>Fri, 23 Jan 2026 13:30:00 GMT</pubDate>
<description>Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.</description>
</item>
<item>
<title>Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-launches-science-mmai-143700756</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-launches-science-mmai-143700756</guid>
<pubDate>Thu, 22 Jan 2026 14:37:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of Science MMAI Gym, a domain-specific training environment designed to transform any causal or frontier Large Language Model (LLM) into a high-performance engine for real-world drug discovery and development tasks.</description>
</item>
<item>
<title>Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-and-hygtia-therapeutics-enter-new-global-strategic-collaboration-to-co-develop-novel-brain-penetrant-nlrp3-inhibitor-for-cns-diseases-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-and-hygtia-therapeutics-enter-new-global-strategic-collaboration-to-co-develop-novel-brain-penetrant-nlrp3-inhibitor-for-cns-diseases-treatment</guid>
<pubDate>Wed, 21 Jan 2026 00:14:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), today announced a co-development collaboration agreement for Insilico's ISM8969 program. Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.</description>
</item>
<item>
<title>Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-completes-first-patient-first-dose-in-bethesda-a-phase-ii-trial-for-garutadustat-ism5411-the-gut-restricted-ai-driven-phd-inhibitor-for-the-treatment-of-inflammatory-bowel-disease</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-completes-first-patient-first-dose-in-bethesda-a-phase-ii-trial-for-garutadustat-ism5411-the-gut-restricted-ai-driven-phd-inhibitor-for-the-treatment-of-inflammatory-bowel-disease</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570), which has recently been granted the generic name of Garutadustat by the United States Adopted Names (USAN) Council. Garutadustat (originally ISM5411) is a novel, gut-restricted PHD inhibitor developed with Pharma.AI, Insilico's generative platform, for the treatment of Inflammato</description>
</item>
<item>
<title>Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-announce-usdollar888-million-multi-year-collaboration-with-servier-for-drug-discovery-and-development-in-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-announce-usdollar888-million-multi-year-collaboration-with-servier-for-drug-discovery-and-development-in-oncology</guid>
<pubDate>Mon, 05 Jan 2026 00:30:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and developing novel therapeutics for challenging targets in the oncology space by leveraging Insilico's proprietary AI platform, Pharma.AI.</description>
</item>
<item>
<title>Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO</title>
<link>https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo</link>
<guid isPermaLink="true">https://6ix.com/company/insilico-medicine-cayman-topco/news/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo</guid>
<pubDate>Tue, 30 Dec 2025 09:00:00 GMT</pubDate>
<description>Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion, achieving the largest biotech IPO in Hong Kong this year, as in the size of fundraising.</description>
</item>
</channel>
</rss>